ImageneBio, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-30

Reporting Person: Atlas Venture Fund X, L.P. (10% Owner)
Reporting Person: ATLAS VENTURE ASSOCIATES X, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates X, LLC (10% Owner)
Reporting Person: Atlas Venture Fund XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, LLC (10% Owner)
Reporting Person: Atlas Venture Opportunity Fund I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	2901609	—	Acquired	2901609	Indirect
2021-03-30	Common Stock	C	1099118	—	Acquired	1268213	Indirect
2021-03-30	Common Stock	C	749634	—	Acquired	749634	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series A Preferred Stock	$	C	9499999	Disposed		Common Stock (1327927)	Indirect
2021-03-30	Series A-1 Preferred Stock	$	C	11258117	Disposed		Common Stock (1573682)	Indirect
2021-03-30	Series A-2 Preferred Stock	$	C	7863094	Disposed		Common Stock (1099118)	Indirect
2021-03-30	Series B Preferred Stock	$	C	5362888	Disposed		Common Stock (749634)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any.

F4: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.